279 related articles for article (PubMed ID: 7908119)
1. Portable device for quantifying parkinsonian wrist rigidity.
Caligiuri MP
Mov Disord; 1994 Jan; 9(1):57-63. PubMed ID: 7908119
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
Peppe A; Dambrosia JM; Chase TN
Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
[No Abstract] [Full Text] [Related]
3. Measurement of rigidity in Parkinson's disease.
Prochazka A; Bennett DJ; Stephens MJ; Patrick SK; Sears-Duru R; Roberts T; Jhamandas JH
Mov Disord; 1997 Jan; 12(1):24-32. PubMed ID: 8990050
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.
Vitek JL; Bakay RA; Freeman A; Evatt M; Green J; McDonald W; Haber M; Barnhart H; Wahlay N; Triche S; Mewes K; Chockkan V; Zhang JY; DeLong MR
Ann Neurol; 2003 May; 53(5):558-69. PubMed ID: 12730989
[TBL] [Abstract][Full Text] [Related]
5. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment.
Hausner RS
J Clin Psychiatry; 1983 Jan; 44(1):13-6. PubMed ID: 6130081
[TBL] [Abstract][Full Text] [Related]
6. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
Shoulson I
Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
[No Abstract] [Full Text] [Related]
7. Zotepine reversibly induces akinesia and rigidity in Parkinson's disease patients with resting tremor or drug-induced psychosis.
Arnold G; Trenkwalder C; Schwarz J; Oertel WH
Mov Disord; 1994 Mar; 9(2):238-40. PubMed ID: 7910949
[No Abstract] [Full Text] [Related]
8. Quantifying rigidity with a new computerized elbow device.
Relja MA; Petravic D; Kolaj M
Clin Neuropharmacol; 1996 Apr; 19(2):148-56. PubMed ID: 8777768
[TBL] [Abstract][Full Text] [Related]
9. Early detection of L-dopa response in parkinsonian patients with a standardized tracking test.
Albani C; Buck A
Adv Neurol; 1993; 60():386-9. PubMed ID: 8420158
[No Abstract] [Full Text] [Related]
10. Clozapine withdrawal symptoms in a Parkinson's disease patient.
Zesiewicz TA; Borra S; Hauser RA
Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
[TBL] [Abstract][Full Text] [Related]
11. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
Facca A; Sanchez-Ramos J
Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
[No Abstract] [Full Text] [Related]
12. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy.
Benbir G; Ozekmekçi S; Apaydin H; Delil S; Erginöz E
Clin Neurol Neurosurg; 2006 Dec; 108(8):726-32. PubMed ID: 16564615
[TBL] [Abstract][Full Text] [Related]
13. A trial of dextromethorphan in parkinsonian patients with motor response complications.
Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN
Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730
[TBL] [Abstract][Full Text] [Related]
14. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
Greene P; Cote L; Fahn S
Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
[No Abstract] [Full Text] [Related]
15. Superior clinical efficacy of Sinement CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open and a double-blind, double-dummy, multicenter treatment evaluation. Dutch Sinement CR Study Group.
Wolters EC; Horstink MW; Roos RA; Jansen EN
Adv Neurol; 1993; 60():648-52. PubMed ID: 8420204
[No Abstract] [Full Text] [Related]
16. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies?
Ransmayr G; Künig G; Neubauer M; Wagner M; Bösch S; Kreczy-Kleedorfer B
Adv Neurol; 1993; 60():685-9. PubMed ID: 8420211
[No Abstract] [Full Text] [Related]
17. Risk factors for drug-induced parkinsonism in tardive dyskinesia patients.
Hansen TE; Brown WL; Weigel RM; Casey DE
J Clin Psychiatry; 1988 Apr; 49(4):139-41. PubMed ID: 2895762
[TBL] [Abstract][Full Text] [Related]
18. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
[TBL] [Abstract][Full Text] [Related]
19. Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.
Zimmerman TR; Sage JI; Lang AE; Mark MH
Mov Disord; 1994 Mar; 9(2):173-7. PubMed ID: 8196678
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
